Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0792
    -0.0037 (-0.35%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    -0.0014 (-0.11%)
     
  • USD/JPY

    151.4320
    +0.1860 (+0.12%)
     
  • Bitcoin USD

    70,897.77
    +1,496.53 (+2.16%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Becton, Dickinson (BDX) Beats On Earnings & Revenues In Q2

Based in New Jersey, Becton, Dickinson and Company BDX is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Currently, Becton, Dickinson has a Zacks Rank #2 (Buy) but that could change following its second-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:

Earnings: Becton, Dickinson’s adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 7 cents and increased 5.5% from $2.18 posted in the year-ago quarter.

Revenues:Adjusted revenues amounted to $2.969 billion, down 3.2% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $2.921 billion.

Becton, Dickinson and Company Price and EPS Surprise

 

Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote

Key Stats: BD Medical generated revenues of $1.987 billion, down 6.8% on a year-over-year basis. BD Life sciences generated revenues of $982 million, up 4.9% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 4%.

Major Factors: Impressive results in the company’s medical segment reflect strong performance in the Medication and Procedural Solutions and Medication Management Solutions units.Notably, within the Medication Management Solutions unit, the Company made some changes to its U.S. dispensing business model.

Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units.

Check back later for our full write up on this Becton, Dickinson and Company earnings report!

Sell These Stocks. Now.

Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. 

See today's Zacks ""Strong Sells"" absolutely free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement